Scarica l'app Stockscreener
2.65
2.57%
-0.07
Precedente Chiudi:
$2.72
Aprire:
$2.78
Volume 24 ore:
51,737
Relative Volume:
0.51
Capitalizzazione di mercato:
$75.79M
Reddito:
$709.00K
Utile/perdita netta:
$-43.14M
Rapporto P/E:
-0.5837
EPS:
-4.54
Flusso di cassa netto:
$-20.35M
1 W Prestazione:
+3.52%
1M Prestazione:
+25.00%
6M Prestazione:
-12.25%
1 anno Prestazione:
-13.68%
Intervallo 1D:
$2.57
$2.79
Intervallo di 1 settimana:
$2.51
$2.8499
Portata 52W:
$1.922
$3.4799
OncoCyte Corporation Stock (OCX) Company Profile
Nome
OncoCyte Corporation
Settore
Industria
Telefono
510-775-0515
Indirizzo
1010 Atlantic Avenue, Suite 102, Alameda, CA
Confronta OCX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OCX
OncoCyte Corporation
|
2.65 | 75.79M | 709.00K | -43.14M | -20.35M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
OncoCyte Corporation Stock (OCX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-05-24 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | Iniziato | Stephens | Overweight |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-03-17 | Ripresa | Needham | Buy |
| 2021-01-07 | Aggiornamento | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | Iniziato | BTIG Research | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | Reiterato | The Benchmark Company | Speculative Buy |
| 2020-07-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | Iniziato | Needham | Buy |
| 2019-02-13 | Iniziato | Piper Jaffray | Overweight |
| 2019-01-29 | Aggiornamento | Janney | Neutral → Buy |
| 2018-12-19 | Ripresa | Lake Street | Buy |
Mostra tutto
OncoCyte Corporation Borsa (OCX) Ultime notizie
OncoCyte Corporation (OCX): Among Cheapest Stocks Insiders Are Buying Recently - Insider Monkey
Oncocyte secures $29.1 million to advance FDA assay - MSN
Broadwood Partners acquires OncoCyte shares worth $9.24 million - MSN
OncoCyte stock hits 52-week low at $1.92 amid market challenges - MSN
Oncocyte corp's Patrick Smith acquires shares worth $2.2 million - MSN
Oncocyte corp CFO buys $200,000 in stock - MSN
Oncocyte corp CFO buys $200,000 in stock By Investing.com - Investing.com Canada
Oncocyte Corp CFO Acquires 97,561 Shares in Private Placement - TradingView
Oncocyte corp's Patrick Smith acquires shares worth $2.2 million By Investing.com - Investing.com South Africa
Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference - The Manila Times
Exclusive: Oncocyte (OCX) CEO & CFO to Meet Top Investors at BTIG's Elite Healthcare Conference - StockTitan
Oncocyte Corp enters into securities purchase agreements - Medical Buyer
Broadwood Partners acquires OncoCyte shares worth $9.24 million By Investing.com - Investing.com Nigeria
Oncocyte Prices $29 Million Stock Offerings -February 10, 2025 at 12:41 pm EST - Marketscreener.com
Oncocyte prices $29.1M equity offering - MSN
Oncocyte Secures $29.1Mln Funding Led By Bio-Rad To Advance Transplant Diagnostics, Stock Down - Nasdaq
OncoCyte’s $29.1M Funding Through Securities Agreements - TipRanks
Oncocyte Prices $29.1 Million Equity Offering - The Manila Times
ForexTV | Small Business Resources - ForexTV.com
Oncocyte (OCX) Secures Game-Changing $29.1M Investment to Revolutionize Early Transplant Rejection Detection - StockTitan
Oncocyte corp investor Patrick Smith buys $1,839 in shares By Investing.com - Investing.com South Africa
Oncocyte corp investor Patrick Smith buys $1,839 in shares - MSN
Oncocyte Corporation (NASDAQ:OCX) Shares Rebounded 7.25% From Their Lows – But Can They Continue? - Marketing Sentinel
Oncocyte corp shareholder Patrick W Smith acquires $34,114 in stock - Investing.com India
Oncocyte corp shareholder Patrick W Smith acquires $34,114 in stock By Investing.com - Investing.com Australia
OncoCyte (STU:7OC0) PS Ratio : 47.04 (As of Jan. 15, 2025) - GuruFocus.com
OncoCyte Co. (NASDAQ:OCX) Shares Bought by Geode Capital Management LLC - Defense World
StockNews.com Initiates Coverage on OncoCyte (NASDAQ:OCX) - Defense World
OncoCyte Corporation (NASDAQ: OCX) Enters Amendment to Lease Agreement with Induce Biologics USA, Inc. and Cushing Ventures, LLCOn January 2, 2025, Oncocyte Corporation announced in a Form 8-K filing that it has entered into an Amendment to a - Defense World
Oncocyte Corp amends lease agreement, sets expiration date By Investing.com - Investing.com Nigeria
Oncocyte Corp amends lease agreement, sets expiration date - Investing.com
Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer - Markets Insider
Oncocyte names Dr. Paul Billings as Consulting CMO - Investing.com India
Oncocyte Taps Harvard-Trained Diagnostics Veteran Dr. Paul Billings as Chief Medical Officer - StockTitan
Medicare expands coverage for kidney transplant test By Investing.com - Investing.com Australia
Oncocyte Expands Market Opportunity for VitaGraft™ Kidney - The Manila Times
OncoCyte Corporation Azioni (OCX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):